Compare Stocks: IMUX, GYRE, OCS, and PHAT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GYRE Gyre Therapeutics	$6.68 +2.1%	$6.32	$5.44 ▼ $9.42	$744.89M	1.92	53,614 shs	52,735 shs
IMUX Immunic	$16.06 -3.1%	$14.45	$5.06 ▼ $16.86	$219.12M	1.41	163,055 shs	79,661 shs
OCS Oculis	$12.94 +0.9%	$12.19	$10.52 ▼ $34.47	$750.31M	0.51	309,445 shs	125,379 shs
PHAT Phathom Pharmaceuticals	$9.58 +4.4%	$10.48	$8.21 ▼ $18.31	$775.03M	0.51	1.73 million shs	968,846 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GYRE Gyre Therapeutics	0.00%	+0.15%	+4.05%	+1.98%	-18.64%
IMUX Immunic	0.00%	+12.31%	+6.85%	+32.95%	+93.66%
OCS Oculis	0.00%	+2.05%	+2.62%	-57.28%	-28.13%
PHAT Phathom Pharmaceuticals	0.00%	+12.05%	-12.67%	-19.29%	-8.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GYRE Gyre Therapeutics	$6.68 +2.1%	$6.32	$5.44 ▼ $9.42	$744.89M	1.92	53,614 shs	52,735 shs
IMUX Immunic	$16.06 -3.1%	$14.45	$5.06 ▼ $16.86	$219.12M	1.41	163,055 shs	79,661 shs
OCS Oculis	$12.94 +0.9%	$12.19	$10.52 ▼ $34.47	$750.31M	0.51	309,445 shs	125,379 shs
PHAT Phathom Pharmaceuticals	$9.58 +4.4%	$10.48	$8.21 ▼ $18.31	$775.03M	0.51	1.73 million shs	968,846 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GYRE Gyre Therapeutics	0.00%	+0.15%	+4.05%	+1.98%	-18.64%
IMUX Immunic	0.00%	+12.31%	+6.85%	+32.95%	+93.66%
OCS Oculis	0.00%	+2.05%	+2.62%	-57.28%	-28.13%
PHAT Phathom Pharmaceuticals	0.00%	+12.05%	-12.67%	-19.29%	-8.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GYRE Gyre Therapeutics	2.25	Hold	$17.00	154.49% Upside
IMUX Immunic	3.00	Buy	$47.57	196.21% Upside
OCS Oculis	2.80	Moderate Buy	$38.00	193.66% Upside
PHAT Phathom Pharmaceuticals	2.88	Moderate Buy	$22.86	138.59% Upside

Current Analyst Ratings Breakdown

Latest IMUX, GYRE, OCS, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
8/14/2026	OCS Oculis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$23.00 ➝ $20.00
8/7/2026	GYRE Gyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
7/31/2026	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/31/2026	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00 ➝ $22.00
7/31/2026	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
7/30/2026	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$28.00 ➝ $22.00
7/29/2026	IMUX Immunic	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	OCS Oculis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	PHAT Phathom Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GYRE Gyre Therapeutics	$116.59M	6.39	$0.22 per share	30.06	$1.28 per share	5.22
IMUX Immunic	N/A	N/A	N/A	N/A	$9.35 per share	N/A
OCS Oculis	N/A	N/A	N/A	N/A	$4.79 per share	N/A
PHAT Phathom Pharmaceuticals	$175.11M	4.43	N/A	N/A	($4.26) per share	-2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GYRE Gyre Therapeutics	$5.03M	-$0.21	N/A	N/A	N/A	-15.47%	-6.57%	-5.35%	N/A
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	N/A
OCS Oculis	-$119.44M	-$1.74	N/A	N/A	N/A	-6,777.18%	-42.61%	-35.23%	N/A
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	8.26	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)

Latest IMUX, GYRE, OCS, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/7/2026	Q2 2026	GYRE Gyre Therapeutics	-$0.0567	-$0.12	-$0.0633	-$0.12	$26.49 million	$29.11 million
8/6/2026	Q2 2026	OCS Oculis	-$0.48	-$0.20	+$0.28	-$0.20	$0.22 million	$0.38 million
6/30/2026	Q2 2026	OCS Oculis	N/A	-$0.20	N/A	-$0.20	N/A	$0.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GYRE Gyre Therapeutics	N/A	4.26	4.06
IMUX Immunic	N/A	5.05	4.92
OCS Oculis	0.01	8.35	8.35
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GYRE Gyre Therapeutics	23.99%
IMUX Immunic	51.82%
OCS Oculis	22.30%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
GYRE Gyre Therapeutics	9.50%
IMUX Immunic	5.49%
OCS Oculis	N/A
PHAT Phathom Pharmaceuticals	9.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GYRE Gyre Therapeutics	40	111.51 million	100.92 million	No Data
IMUX Immunic	70	13.64 million	12.90 million	Optionable
OCS Oculis	2	57.98 million	N/A	Not Optionable
PHAT Phathom Pharmaceuticals	110	80.90 million	73.35 million	Optionable

IMUX, GYRE, OCS, and PHAT Headlines

Recent News About These Companies

Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth

August 15 at 8:31 PM | tipranks.com

Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT

August 11, 2026 | marketbeat.com

Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT

August 9, 2026 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5% - Here's Why

August 4, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

August 4, 2026 | globenewswire.com

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

August 3, 2026 | businesswire.com

925,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Perceptive Advisors LLC

August 2, 2026 | marketbeat.com

Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 1, 2026 | seekingalpha.com

Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4

August 1, 2026 | seekingalpha.com

PHAT stock clocks worst day in over 1.5 years — what sparked the selloff?

July 30, 2026 | msn.com

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Phathom Pharmaceuticals (PHAT) Q2 2026 Earnings

July 30, 2026 | 247wallst.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Expectations By $0.02 EPS

July 30, 2026 | marketbeat.com

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

July 30, 2026 | prnewswire.com

Needham & Company LLC Has Lowered Expectations for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price

July 30, 2026 | marketbeat.com

Phathom Pharmaceuticals Q2 Earnings Call Highlights

July 30, 2026 | marketbeat.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

July 30, 2026 | zacks.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Down on Disappointing Earnings

July 30, 2026 | marketbeat.com

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

July 30, 2026 | globenewswire.com

Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q2 2026 Result

July 29, 2026 | finance.yahoo.com

625,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by EcoR1 Capital LLC

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, GYRE, OCS, and PHAT Company Descriptions

Gyre Therapeutics NASDAQ:GYRE

$6.68 +0.14 (+2.14%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.68 0.00 (-0.07%)

As of 08/14/2026 07:34 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Immunic NASDAQ:IMUX

$16.06 -0.52 (-3.14%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$16.08 +0.02 (+0.15%)

As of 08/14/2026 07:55 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Oculis NASDAQ:OCS

$12.94 +0.12 (+0.94%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$12.96 +0.03 (+0.19%)

As of 08/14/2026 07:34 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.58 +0.40 (+4.36%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$9.59 +0.01 (+0.05%)

As of 08/14/2026 07:34 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMUX, GYRE, OCS, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMUX, GYRE, OCS, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMUX, GYRE, OCS, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, GYRE, OCS, and PHAT Company Descriptions

Gyre Therapeutics NASDAQ:GYRE

Immunic NASDAQ:IMUX

Oculis NASDAQ:OCS

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMUX, GYRE, OCS, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMUX, GYRE, OCS, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMUX, GYRE, OCS, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, GYRE, OCS, and PHAT Company Descriptions

Gyre Therapeutics NASDAQ:GYRE

Immunic NASDAQ:IMUX

Oculis NASDAQ:OCS

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools